Pharmacogenomics

ISBN-13: 9780471227694 / Angielski / Twarda / 2003 / 368 str.

Mark A. Rothstein; Francis S. Collins

Opis

Through analyses of the complex underlying issues, this interdisciplinary volume frames the agenda for dealing with genetic variation and incorporating pharmacogenomics into health care. The three sections of this book, Research Issues, Clinical Issues, and Social Perspectives address key elements integral to a comprehensive discussion of this emerging field. This groundbreaking text...

• Examines new research strategies, methodologies, and ethical and social considerations of pharmacogenomics
• Addresses practical considerations of anticipated changes in education, training, oversight, guidelines and protocols, and continuing education requirements
• Provides analyses of the potential enormous impact of pharmacogenomics, such as in the standard of care and treatment, including perspectives from the fields of anthropology, law, ethics, and economics

Recenzje

"The discussion of societal, legal, economic, and governmental issues go well beyond the sphere of pharmogenomics." ( American Journal for Medical Genetics, September 1, 2005)

"...indispensable guide...as timely as it can be...an impressive multidisciplinary analysis...a ′must read′..." (Bioethics, Vol 18(4), August 2004)

" Pharmacogenomics is highly recommended for anyone with an interest in the field . Given this book′s uniqueness libraries at any institution teaching pharmcogenomics should have a copy of this book. (Journal of Pharmacy Technology, Sept/Oct 2003)

"...well written, clear, and informative...a restrained sense of excitement...permeates throughout...clearly...a solid contribution to the discourse." (Nature Biotechnology, May 1, 2003)

"...chapters offer fascinating glimpses into fields that may not be familiar to geneticists, genomicists, or clinicians...they will be informative...and provide a reminder that many people outside this field are going to be paying a lot of attention as discoveries...are reported." (New England Journal of Medicine, July 24, 2003)

"...an excellent summary of aspects of phamacogenomics...a solid reference for those working in the field and a unique textbook for those new to the subject area." (Clinical Chemistry, Vol. 49, No. 9)

"...a welcome addition to the growing body of literature...highly recommended for anyone with an interest in the field...should be required reading for anyone conducting pharmacogenomic research and for all clinicians who use pharmacogenomics..." (Journal of Pharmacy Technology, Vol. 19September/October 2003)

"...addresses the ethical, legal, and social implications of the individualized medicine that pharmacogenomics stands to create..." (Genetic Engineering News, Vol 23(14), 2003)

Spis treści

Foreword (F. Collins).

Preface.

PART I: INTRODUCTION: SCIENCE AND SOCIETY.

Public Attitudes About Pharmacogenomics (M. Rothstein, et al.).

Pharmacogenomics:  Pharmacology and Toxicology in the Genomics (H. Mohrenweiser).

The Implications of Population Genetics for Pharmacogenomics (C. Hanis).

PART II: RESEARCH AND DEVELOPMENT CHALLENGES AND CONSIDERATIONS.

Genome Research and Minorities (H. Greely).

Drug Development Strategies (P. Manasco & T. Arledge).

Drug Development,  Regulation, and Genetically Guided Therapy Pharmacogenomics (D. Feigal & S. Gutman).

Intellectual Property and Commercial Aspects of Pharmacogenomics (A. Nunnally,  et al.).

PART III: CLINICAL APPLICATIONS.

Integration of Pharmacogenomics into Medical Practice (G. Omenn & A. Motulsky).

Clinical Utility Pharmacogenetics and Pharmacogenomics (N. Holtzman).

Medical Liability for Pharmacogenomics (L. Palmer).

The Challenges of Pharmacogenomics for Pharmacy Education, Practice, and Regulation  (D. Brushwood).

PART IV: THE SOCIAL DIMENSION.

Economic Implications of Pharmacogenomics (C. Reeder & W. Dickson). 

 Pharmacogenomics and the Social Construction of Identity (M. Foster).

Pharmacogenomics: Considerations for Communities of Color (L. Nsiah–Jefferson).

Constitutional Issues in the Use of Pharmacogenomic Variations Associated with Race (J. Robertson).

PART V: EPILOGUE: POLICY PRESCRIPTIONS (M. Rothstein).

Pharmacogenomics and Minority Populations: General Population Survey Questionnaire (M. Rothstein).

Index.

O autorze

Mark A. Rothstein holds the Herbert F. Boehl Chair of Law and Medicine and is Director of the Institute for Bioethics, Health Policy and Law at the University of Louisville. He has appointments in the Departments of Medicine and Family and Community Medicine at the School of Medicine and at the Louis D. Brandeis School of Law. Professor Rothstein is a leading authority on genetics, privacy, and health policy. He has served as an advisor to the NIH, CDC, DOE, Institute of Medicine, National Conference of State Legislatures, and numerous other public and professional entitles.

Blurb

"In this remarkably broad and far–reaching work, editor Mark Rothstein and his distinguished list of contributors have laid out an impressive framework for the field. Beginning with a survey of public attitudes, and progressing through scientific, clinical, governmental, legal, economic, and societal issues, the text builds to a final provocative epilogue on consequences for public policy."
–from the Foreword by Francis S. Collins

Pharmacogenomics promises to revolutionize medicine by enabling the prevention, diagnosis, and treatment of diseases at the genome level. While a substantial amount of public and private research focuses on new pharmacogenomic applications, notably less attention has been directed to the ethical, legal, and social implications of "individualized medicine." Mark Rothstein′s timely anthology reduces that scholarship deficit, presenting a multidisciplinary analysis of the scientific, clinical, economic, ethical, social, and legal implications of pharmacogenomics.

Assembling an all–star cast of bioethical scholars, medical researchers, legal scholars, and social scientists, Mark Rothstein examines the promises, questions, and concerns these revolutionary therapies implicitly present. Among other features, Pharmacogenomics:
∗ Reports for the first time the results of the first detailed, national survey of public attitudes regarding pharmacogenomics
∗ Covers informed consent, privacy, confidentiality, and risk–benefit evaluations
∗ Analyzes the potentially enormous changes in the standard of care and the approach to treatment with the development and application of pharmacogenomic technology
∗ Addresses practical considerations of education, training, oversight, guidelines and protocols, and continuing education requirements
∗ Recommends approaches to respond to the more complex issues of safety, efficacy, and quality in the distribution and development of individualized therapies
∗ Explores the new legal standards and implementation challenges
∗ Offers a policy framework that balances the benefits and risks and considers the wide range of legislative, regulatory, and professional options

Biotechnology and pharmaceutical researchers and regulators, health care professionals and students, and academics and policymakers will find Pharmacogenomics to be a valuable resource.